Letter of Intent for a Memorandum of Understanding for the French-British Strategic Genomics Research and Development Partnership between

the French National Institute For Health and Medical Research (INSERM)

and

Genomics England Ltd

The Institut National de la Santé et de la Recherche Médicale (Inserm), with registered office in Paris (France) represented by its President and CEO, Prof. Yves Lévy, acting in the name and on behalf of the members of the French National Alliance for Life Sciences and Health (Aviesan), the umbrella organisation in France which will notably lead and deliver the plan “France Médecine Génomique 2025”

And

Genomics England Ltd owned by the Department of Health and Social Care of the United Kingdom which is responsible for delivering the 100,000 Genomes Project working with the National Health Service.

Considering

That France and United Kingdom share the ambition of building and operating the most advanced a competitive Genomic Healthcare and Research in the World. Both Nations are international leaders in genomic medicine having discovered the structure of DNA, invented modern approaches to reading the genetic code, built the genetic and physical maps of the human genome and applied it to make major advances across a range of diseases with global impact. They have complimentary but distinct initiatives representing the most ambitious and largest public commitments in the World to create the talent and infrastructure to deliver a global leading 21st Century genomic medicine service. This common vision for genomics and our shared national attributes make it precisely the time to consider how a partnership could accelerate genomic healthcare and industrial collaboration.
With the objective of:

Building common approaches to standardisation. France and the United Kingdom will develop standard setting that ensures both nations adopt new technologies appropriately whilst moving at the best speed and pace. These approaches are focused on areas where such a strategic alliance will make these happen much faster and more successfully by combining the attributes and research endeavour of both Nations and their respective research and healthcare infrastructure.

Inserm

________________________
President & CEO Inserm
President Aviesan
Date, Place: ____________________

Genomics England

________________________
Executive Chairman of Genomics England Ltd.
Genomics England
Date, Place: ________________